Merck KGaA To Launch Parkinson's Agent Sarizotan In 2007
The serotonin agonist/dopamine antagonist will enter Phase III studies this year for L-dopa-induced dyskinesia in Parkinson's patients.
The serotonin agonist/dopamine antagonist will enter Phase III studies this year for L-dopa-induced dyskinesia in Parkinson's patients.